PRAMIPEXOLE GxP pramipexole dihydrochloride 0.25 mg tablets blister pack

País: Australia

Idioma: inglés

Fuente: Department of Health (Therapeutic Goods Administration)

Ingredientes activos:

pramipexole dihydrochloride monohydrate, Quantity: 0.25 mg

Disponible desde:

Arrotex Pharmaceuticals Pty Ltd

Designación común internacional (DCI):

pramipexole dihydrochloride monohydrate

formulario farmacéutico:

Tablet, uncoated

Composición:

Excipient Ingredients: mannitol; pregelatinised maize starch; magnesium stearate; povidone; silicon dioxide

Vía de administración:

Oral

Unidades en paquete:

10, 30, 100

tipo de receta:

(S4) Prescription Only Medicine

indicaciones terapéuticas:

Pramipexole tablets are indicated for:,-the treatment of signs and symptoms of idiopathic Parkinson's disease. It may be used as monotherapy or in combination with levodopa.

Resumen del producto:

Visual Identification: White, oval, uncoated tablets debossed with 'CL' and '3' on one side with breakline in between and a breakline on the other side.; Container Type: Blister Pack; Container Material: Al/Al; Container Life Time: 3 Years; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

Estado de Autorización:

Licence status A

Fecha de autorización:

2014-09-23